North America and Europe PEGylated Drugs Market to touch $10.5 bn by 2024
Sellbyville, DE -- (SBWIRE) -- 12/10/2018 -- Global North America and Europe PEGylated Drugs Market set to exceed USD 10.5 billion by 2024; according to a new research report by Global Market Insights.
Increasing R&D investment of biotechnology & pharmaceutical companies to develop enhanced PEGylated drugs for treatment of various chronic diseases along with rising occurrence of chronic ailments in developed regions will propel PEGylated drugs market growth over the forecast period. Major advancements in biologics sector including advances in drug antibody conjugates, and immunotherapies will positively impact market growth.
Moreover, rising incidences of chronic ailments and increasing death rates associated with cancer in Canada will propel industry growth. However, the side-effects associated with pegylated drugs along with drug failure will impede PEGylated drugs market growth over the forecast timeframe.
Request for a sample of this research report @ https://www.gminsights.com/request-sample/detail/2511
Company profiled in this report based on Business overview, Financial data, Product landscape, Strategic outlook & SWOT analysis:
- Novo Nordisk
- Merck KGaA
Cancer segment held over 60% of the overall market share in 2017 due to growing prevalence of the disease creating a demand for the development of effective drugs. Benefits offered by PEGylated drugs such as reduced proteolytic degradation along with minimized immunogenicity leading to enhanced therapeutic efficacy will propel market growth. Increasing areas of applications as well as rising adoption of PEGylated drugs to treat various types of cancer will stimulate business growth.
Hepatitis segment size was USD 156 million in 2017 and is anticipated to follow a declining trend over the forecast period. However, increasing focus of industry players to develop pegylated drugs used for the treatment of such chronic conditions will contribute to market growth. For instance, launch of Pegasys drug used for treating Hepatitis C in adult patients will fuel market growth.
Canada PEGylated drugs market will witness over 5.5% CAGR from 2018 to 2024. Increasing prevalence of chronic ailments such as cancer will drive the business growth. As per Canadian Cancer Society, more than two lac people are diagnosed with cancer in 2017 that will surge demand for pegylated drugs in the future. Development and availability of various pegylated drugs including Onivyde, Plegridy, Oncaspar and others for treatment of several chronic ailments are factors accelerating business growth over the forecast timeframe.
Italy PEGylated drugs market was USD 218 million in 2017 and is anticipated to witness 9% CAGR over the coming few years. Increasing usage of peg-interferons for the treatment of Hepatitis C and soaring adoption of PEG-IFN beta-1a injectables for the treatment of patients with multiple sclerosis will foster North America and Europe PEGylated Drugs Market growth. Few notable industry players operating in North America and Europe PEGylated drugs market are Shire Group, UCB, Merck, AstraZeneca, Amgen, Sigma Tau, Biogen, Pfizer and Roche. Industry players attempt to develop enhanced and effective PEGylated drugs for treating chronic conditions. Robust pipeline and ongoing research studies coupled with high R&D investment in PEGylation technology is anticipated to propel industry growth.
Make an inquiry for purchasing this report @ https://www.gminsights.com/inquiry-before-buying/2511
North America & Europe PEGylated Drugs Market by Disease Indication
o Multiple sclerosis
o Gastrointestinal disorders
North America & Europe PEGylated Drugs Market by Type
o Monoclonal antibodies (mAbs)
o Colony stimulating factors